Uses, Effects and Toxicity of Synthetic Cannabinoids from the Perspective of People with Lived Experiences

References

• Adamowicz, P., J. Gieron, D. Gil, W. Lechowicz, A. Skulska, and B. Tokarczyk. 2017. The effects of synthetic cannabinoid UR-144 on the human body-A review of 39 cases. Forensic Science International 273:e18–e21. doi:10.1016/j.forsciint.2017.02.031.
   PubMed Web of Science ®Google Scholar
• Ashton, J. C., J. L. Wright, J. M. McPartland, and J. D. Tyndall. 2008. Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists. Current Medicinal Chemistry 15 (14):1428–43. doi:10.2174/092986708784567716.
   PubMed Web of Science ®Google Scholar
• Auwarter, V., S. Dresen, W. Weinmann, M. Muller, M. Putz, and N. Ferreiros. 2009. ‘Spice’ and other herbal blends: Harmless incense or cannabinoid designer drugs? Journal of Mass Spectrometry : JMS 44 (5):832–37. doi:10.1002/jms.v44:5.
   PubMed Web of Science ®Google Scholar
• Banerjee, S. P., S. H. Snyder, and R. Mechoulam. 1975. Cannabinoids: Influence on neurotransmitter uptake in rat brain synaptosomes. The Journal of Pharmacology and Experimental Therapeutics 194 (1):74–81.
   PubMed Web of Science ®Google Scholar
• Bilgrei, O. R. 2016. From “herbal highs” to the “heroin of cannabis”: Exploring the evolving discourse on synthetic cannabinoid use in a Norwegian Internet drug forum. The International Journal on Drug Policy 29:1–8. doi:10.1016/j.drugpo.2016.01.011.
   PubMed Web of Science ®Google Scholar
• Castaneto, M. S., D. A. Gorelick, N. A. Desrosiers, R. L. Hartman, S. Pirard, and M. A. Huestis. 2014. Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications. Drug and Alcohol Dependence 144:12–41. doi:10.1016/j.drugalcdep.2014.08.005.
   PubMed Web of Science ®Google Scholar
• Castellanos, D., S. Singh, G. Thornton, M. Avila, and A. Moreno. 2011. Synthetic cannabinoid use: A case series of adolescents. The Journal of Adolescent Health : Official Publication of the Society for Adolescent Medicine 49 (4):347–49. doi:10.1016/j.jadohealth.2011.08.002.
   PubMed Web of Science ®Google Scholar
• Center for Behavioral Health Statistics and Quality. 2017. Results from the 2016 national survey on drug use and health: Detailed tables. Rockville: Substance Abuse and Mental Health Services Administration.
   Google Scholar
• Cooper, Z. D. 2016. Adverse effects of synthetic cannabinoids: Management of acute toxicity and withdrawal. Current Psychiatry Reports 18 (5):52. doi:10.1007/s11920-016-0694-1.
   PubMed Web of Science ®Google Scholar
• Corazza, O., S. Assi, P. Simonato, J. Corkery, F. S. Bersani, Z. Demetrovics, J. Stair, S. Fergus, C. Pezzolesi, M. Pasinetti, et al. 2013. Promoting innovation and excellence to face the rapid diffusion of novel psychoactive substances in the EU: The outcomes of the ReDNet project. Human Psychopharmacology: Clinical and Experimental 28 (4):317–23. doi:10.1002/hup.2299.
   PubMed Web of Science ®Google Scholar
• Corazza, O., G. Valeriani, F. S. Bersani, J. Corkery, G. Martinotti, G. Bersani, and F. Schifano. 2014. “Spice,” “kryptonite,” “black mamba”: An overview of brand names and marketing strategies of novel psychoactive substances on the web. Journal of Psychoactive Drugs 46 (4):287–94. doi:10.1080/02791072.2014.944291.
   PubMed Web of Science ®Google Scholar
• Davey, Z., F. Schifano, O. Corazza, and P. Deluca. 2012. e-Psychonauts: Conducting research in online drug forum communities. Journal of Mental Health 21 (4):386–94. doi:10.3109/09638237.2012.682265.
   PubMed Web of Science ®Google Scholar
• Deluca, P., Z. Davey, O. Corazza, L. Di Furia, M. Farre, L. H. Flesland, M. Mannonen, A. Majava, T. Peltoniemi, M. Pasinetti, et al. 2012. Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. Progress in Neuro-Psychopharmacology and Biological Psychiatry 39 (2):221–26. doi:10.1016/j.pnpbp.2012.07.011.
   PubMed Web of Science ®Google Scholar
• Elsohly, M. A., W. Gul, A. S. Wanas, and M. M. Radwan. 2014. Synthetic cannabinoids: Analysis and metabolites. Life Sciences 97 (1):78–90. doi:10.1016/j.lfs.2013.12.212.
   PubMed Web of Science ®Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction. 2005. Differences in patterns of drug use between women and men. Luxembourg: European Monitoring Centre for Drugs and Drug Addiction.
   Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction. 2019. European drug report 2019: Trends and developments. Luxembourg: European Monitoring Centre for Drugs and Drug Addiction.
   Google Scholar
• Every-Palmer, S. 2011. Synthetic cannabinoid JWH-018 and psychosis: An explorative study. Drug and Alcohol Dependence 117 (2–3):152–57. doi:10.1016/j.drugalcdep.2011.01.012.
   PubMed Web of Science ®Google Scholar
• Fattore, L., and W. Fratta. 2011. Beyond THC: The new generation of cannabinoid designer drugs. Frontiers in Behavioral Neuroscience 5:60. doi:10.3389/fnbeh.2011.00060.
   PubMed Web of Science ®Google Scholar
• Forrester, M. B., K. Kleinschmidt, E. Schwarz, and A. Young. 2012. Synthetic cannabinoid and marijuana exposures reported to poison centers. Human & Experimental Toxicology 31 (10):1006–11. doi:10.1177/0960327111421945.
   PubMed Web of Science ®Google Scholar
• Gummin, D. D., J. B. Mowry, D. A. Spyker, D. E. Brooks, K. M. Osterthaler, and W. Banner. 2018. 2017 annual report of the American Association of poison control centers’ national poison data system (NPDS): 35th annual report. Clinical Toxicology 56 (12):1213–415. doi:10.1080/15563650.2018.1533727.
   PubMed Web of Science ®Google Scholar
• Gunderson, E. W., H. M. Haughey, N. Ait-Daoud, A. S. Joshi, and C. L. Hart. 2012. “Spice” and “K2” herbal highs: A case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. The American Journal on Addictions 21 (4):320–26. doi:10.1111/ajad.2012.21.issue-4.
   PubMed Web of Science ®Google Scholar
• Heltsley, R., M. K. Shelby, D. J. Crouch, D. L. Black, T. A. Robert, L. Marshall, C. L. Bender, A. Z. DePriest, and M. A. Colello. 2012. Prevalence of synthetic cannabinoids in U.S. athletes: Initial findings. Journal of Analytical Toxicology 36 (8):588–93. doi:10.1093/jat/bks066.
   PubMed Web of Science ®Google Scholar
• Hermanns-Clausen, M., S. Kneisel, B. Szabo, and V. Auwarter. 2013. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: Clinical and laboratory findings. Addiction 108 (3):534–44. doi:10.1111/add.2013.108.issue-3.
   PubMed Web of Science ®Google Scholar
• Higgins, K., N. O’Neill, L. O’Hara, J. A. Jordan, M. McCann, T. O’Neill, M. Clarke, and A. Campbell. 2019. Evidence for public health on novel psychoactive substances: A mixed method study. 14th ed. UK: National Institute of Health Research Public Health Research Programme.
   Google Scholar
• Hoyte, C. O., J. Jacob, A. A. Monte, M. Al-Jumaan, A. C. Bronstein, and K. J. Heard. 2012. A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Annals of Emergency Medicine 60 (4):435–38. doi:10.1016/j.annemergmed.2012.03.007.
   PubMed Web of Science ®Google Scholar
• Kassai, S., J. N. Pinter, J. Racz, B. Borondi, T. Toth-Kariko, K. Kerekes, and V. A. Gyarmathy. 2017. Assessing the experience of using synthetic cannabinoids by means of interpretative phenomenological analysis. Harm Reduction Journal 14 (1):9. doi:10.1186/s12954-017-0138-1.
   PubMed Web of Science ®Google Scholar
• Kendall, D. A., and G. A. Yudowski. 2016. Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease. Frontiers in Cellular Neuroscience 10:294. doi:10.3389/fncel.2016.00018.
   PubMed Web of Science ®Google Scholar
• Kikura-Hanajiri, R., N. Uchiyama, M. Kawamura, and Y. Goda. 2013. Changes in the prevalence of synthetic cannabinoids and cathinone derivatives in Japan until early 2012. Forensic Toxicology 31:44–53. doi:10.1007/s11419-012-0165-2.
   Web of Science ®Google Scholar
• Kjellgren, A., H. Henningsson, and C. Soussan. 2013. Fascination and social togetherness-discussions about spice smoking on a Swedish Internet Forum. Substance Abuse : Research and Treatment 7:191–98. doi:10.4137/SART.S13323.
   PubMedGoogle Scholar
• Kronstrand, R., M. Roman, M. Andersson, and A. Eklund. 2013. Toxicological findings of synthetic cannabinoids in recreational users. Journal of Analytical Toxicology 37 (8):534–41. doi:10.1093/jat/bkt068.
   PubMed Web of Science ®Google Scholar
• Küçük, E., H. Çoban, A. T. Kliniği, and G. H. Kliniği. 2016. The effects of synthetic cannabinoids on alveolar-arterial oxygen gradient. Journal of Clinical and Analytical Medicine 7:610–13. doi:10.4328/JCAM.3153.
   Web of Science ®Google Scholar
• Le Boisselier, R., J. Alexandre, V. Lelong-Boulouard, and D. Debruyne. 2017. Focus on cannabinoids and synthetic cannabinoids. Clinical Pharmacology and Therapeutics 101 (2):220–29. doi:10.1002/cpt.563.
   PubMed Web of Science ®Google Scholar
• Loeffler, G., E. Delaney, and M. Hann. 2016. International trends in spice use: Prevalence, motivation for use, relationship to other substances, and perception of use and safety for synthetic cannabinoids. Brain Research Bulletin 126 (Pt 1):8–28. doi:10.1016/j.brainresbull.2016.04.013.
   PubMed Web of Science ®Google Scholar
• McQuade, D., S. Hudson, P. I. Dargan, and D. M. Wood. 2013. First European case of convulsions related to analytically confirmed use of the synthetic cannabinoid receptor agonist AM-2201. European Journal of Clinical Pharmacology 69 (3):373–76. doi:10.1007/s00228-012-1379-2.
   PubMed Web of Science ®Google Scholar
• Papanti, D., F. Schifano, G. Botteon, F. Bertossi, J. Mannix, D. Vidoni, M. Impagnatiello, E. Pascolo-Fabrici, and T. Bonavigo. 2013. “Spiceophrenia”: A systematic overview of “spice”-related psychopathological issues and a case report. Human Psychopharmacology: Clinical and Experimental 28 (4):379–89. doi:10.1002/hup.2312.
   PubMed Web of Science ®Google Scholar
• Pertwee, R. G. 2006. Cannabinoid pharmacology: The first 66 years. British Journal of Pharmacology 147 (Suppl 1):S163–71. doi:10.1038/sj.bjp.0706406.
   PubMed Web of Science ®Google Scholar
• Prilutskaya, M., F. S. Bersani, O. Corazza, and S. Molchanov. 2017. Impact of synthetic cannabinoids on the duration of opioid-related withdrawal and craving among patients of addiction clinics in Kazakhstan: A prospective case-control study. Human Psychopharmacology: Clinical and Experimental 32 (3). doi:10.1002/hup.v32.3.
   PubMed Web of Science ®Google Scholar
• Robinson, K. M. 2001. Unsolicited narratives from the Internet: A rich source of qualitative data. Qualitative Health Research 11 (5):706–14. doi:10.1177/104973201129119398.
   PubMed Web of Science ®Google Scholar
• Schifano, F., F. Napoletano, S. Chiappini, A. Guirguis, J. M. Corkery, S. Bonaccorso, A. Ricciardi, N. Scherbaum, and A. Vento. 2019. New/emerging psychoactive substances and associated psychopathological consequences. Psychological Medicine, 1–13.
   Google Scholar
• Schneir, A. B., J. Cullen, and B. T. Ly. 2011. “Spice” girls: Synthetic cannabinoid intoxication. The Journal of Emergency Medicine 40 (3):296–99. doi:10.1016/j.jemermed.2010.10.014.
   PubMed Web of Science ®Google Scholar
• Soussan, C., and A. Kjellgren. 2014. Harm reduction and knowledge exchange-a qualitative analysis of drug-related Internet discussion forums. Harm Reduction Journal 11:25. doi:10.1186/1477-7517-11-25.
   PubMed Web of Science ®Google Scholar
• Spaderna, M., P. H. Addy, and D. C. D’Souza. 2013. Spicing things up: Synthetic cannabinoids. Psychopharmacology 228 (4):525–40. doi:10.1007/s00213-013-3188-4.
   PubMed Web of Science ®Google Scholar
• Steffens, M., and T. J. Feuerstein. 2004. Receptor-independent depression of DA and 5-HT uptake by cannabinoids in rat neocortex–involvement of Na(+)/K(+)-ATPase. Neurochemistry International 44 (7):529–38. doi:10.1016/j.neuint.2003.08.009.
   PubMed Web of Science ®Google Scholar
• Szabo, B., and E. Schlicker. 2005. Effects of cannabinoids on neurotransmission. Handbook of Experimental Pharmacology 168:327–65.
   Google Scholar
• Thayer, S. E., and S. Ray. 2006. Online communication preferences across age, gender, and duration of Internet use. CyberPsychology & Behavior 9 (4):432–40. doi:10.1089/cpb.2006.9.432.
   PubMedGoogle Scholar
• Tung, C. K., T. P. Chiang, and M. Lam. 2012. Acute mental disturbance caused by synthetic cannabinoid: A potential emerging substance of abuse in Hong Kong. East Asian Archives of Psychiatry : Official Journal of the Hong Kong College of Psychiatrists = Dong Ya Jing Shen Ke Xue Zhi : Xianggang Jing Shen Ke Yi Xue Yuan Qi Kan 22 (1):31–33.
   PubMedGoogle Scholar
• Vandrey, R., K. E. Dunn, J. A. Fry, and E. R. Girling. 2012. A survey study to characterize use of Spice products (synthetic cannabinoids). Drug and Alcohol Dependence 120 (1–3):238–41. doi:10.1016/j.drugalcdep.2011.07.011.
   PubMed Web of Science ®Google Scholar
• Wells, D. L., and C. A. Ott. 2011. The “new” marijuana. The Annals of Pharmacotherapy 45 (3):414–17. doi:10.1345/aph.1P580.
   PubMed Web of Science ®Google Scholar
• Winstock, A. R., and M. J. Barratt. 2013. Synthetic cannabis: A comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug and Alcohol Dependence 131 (1–2):106–11. doi:10.1016/j.drugalcdep.2012.12.011.
   PubMed Web of Science ®Google Scholar
• Zawilska, J. B., and J. Wojcieszak. 2014. Spice/K2 drugs–more than innocent substitutes for marijuana. The International Journal of Neuropsychopharmacology 17 (3):509–25. doi:10.1017/S1461145713001247.
   PubMed Web of Science ®Google Scholar